Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia.

Trial Profile

Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Epoetin alfa (Primary) ; Ribavirin (Primary) ; Boceprevir; Peginterferon alfa-2b
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2012 Results have been presented at the International Liver Congress(TM)/47th European Association for the Study of the Liver (EASL) annual meeting, according to a Merck media release.
    • 19 Apr 2012 Results will be presented at the International Liver Congress(TM)/47th European Association for the Study of the Liver (EASL) annual meeting, according to a Merck media release.
    • 19 Apr 2012 Results published in a Merck media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top